Alexion's Soliris Could Benefit From Japan's Orphan Drug Pricing Policy
This article was originally published in PharmAsia News
Executive Summary
U.S. biotech firm Alexion Pharmaceuticals, which submitted a NDA in Japan for Soliris (eculizumab) for patients with rare paroxysmal nocturnal hemoglobinuria blood disorder, could benefit from the country's practice of placing a premium on innovative drugs for orphan diseases
You may also be interested in...
Alexion Eyes Soliris' Japan Launch, Analysts Upbeat About Pricing And Market Size
Japan's Ministry of Health, Labor and Welfare recently approved Alexion Pharmaceutical's Soliris (eculizumab) for the rare blood disorder paroxysmal nocturnal hemoglobinuria, and analysts believe it may beat initial expectations once it hits the market
Alexion Eyes Soliris' Japan Launch, Analysts Upbeat About Pricing And Market Size
Japan's Ministry of Health, Labor and Welfare recently approved Alexion Pharmaceutical's Soliris (eculizumab) for the rare blood disorder paroxysmal nocturnal hemoglobinuria, and analysts believe it may beat initial expectations once it hits the market
Takeda's Alogliptin Among MHLW Approval Recommendations; Pfizer, Alexion Also Gain
Japan's First Committee on New Drugs at the Ministry of Health, Labor and Welfare recommended for approval three Takeda drugs: alogliptin and pioglitazone/metformin combination - both for type 2 diabetes - and combination drug candesartan/amlodipine for hypertension